The facility, which is expected to come online in early 2016, will support Juno’s planned JCAR015 multicenter clinical trial, additional clinical programs in Juno’s pipeline, and the company’s first commercial products.
"The Bothell manufacturing facility is an important milestone for Juno," said Hans Bishop, CEO and president of Juno.
"The manufacturing expertise we are developing is key to our long term success, increasing our ability to run multiple clinical trials and commercialize our pipeline, and as a platform to introduce the various innovations we are investing in to optimize patient outcomes."
Washington governor Jay Inslee stated, "We are thrilled to have Juno as a part of our life science ecosystem and look forward to supporting the growth of this industry. The expansion of Juno Therapeutics’ manufacturing presence in Washington state will increase Juno’s ability to provide their potentially lifesaving treatments to more patients across the country and will produce high wage jobs in the region."
Juno will continue to work with its existing contract manufacturing partners to augment its manufacturing capabilities. Among other advantages, this will enhance flexibility, provide redundancy, and increase capacity in a cost effective manner.